Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H32N2O2.2ClH |
| Molecular Weight | 441.434 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=C(OC)C=C(CCN2CCN(CCCC3=CC=CC=C3)CC2)C=C1
InChI
InChIKey=XWOXAKBQEMQMFH-UHFFFAOYSA-N
InChI=1S/C23H32N2O2.2ClH/c1-26-22-11-10-21(19-23(22)27-2)12-14-25-17-15-24(16-18-25)13-6-9-20-7-4-3-5-8-20;;/h3-5,7-8,10-11,19H,6,9,12-18H2,1-2H3;2*1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H32N2O2 |
| Molecular Weight | 368.5124 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Cutamesine, an agonsit of brain sigma 1 receptors, was developed by Santen Pharmaceutical for the treatment of cognitive diseases. The drug was tested in phase II in patients with major depressive disorders and for recovery of patients with stroke, however its development was terminated for the given conditions. Currently M's science corporation is developing cutamesine for Amyotrophic lateral sclerosis and Retinitis pigmentosa as more suitable target diseases.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL287 |
17.4 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases. | 2010-06-24 |
|
| Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. | 2010-04-24 |
|
| Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. | 2010-04-24 |
|
| Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. | 2010-03-06 |
|
| Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease. | 2010-01-20 |
|
| Pharmacology and therapeutic potential of sigma(1) receptor ligands. | 2008-12 |
|
| Role of N-methyl-D-aspartate receptors in antidepressant-like effects of sigma 1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats. | 2007-09 |
|
| In vivo evaluation of radioiodinated 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)-piperazine derivatives as new ligands for sigma receptor imaging using single photon emission computed tomography. | 2006-10 |
|
| Synthesis and in vitro evaluation of iodinated derivatives of piperazine as a new ligand for sigma receptor imaging by single photon emission computed tomography. | 2006-04 |
|
| Involvement of kappa-opioid and sigma receptors in short-term memory in mice. | 2002-10-18 |
|
| The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. | 2001-08-24 |
|
| Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. | 2001-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25270629
Patients with stroke receive cutamesine at a dose of 1 mg/day or 3 mg/day for 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24334165
Mice motor neuron cells were treated with cutamesine at concentration of 1-10 uM and the drug was shown to reduce SOD1(G93A)-induced cell death in a concentration-dependent manner.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 22:58:11 GMT 2025
by
admin
on
Tue Apr 01 22:58:11 GMT 2025
|
| Record UNII |
B66RO93FXQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
165377-44-6
Created by
admin on Tue Apr 01 22:58:11 GMT 2025 , Edited by admin on Tue Apr 01 22:58:11 GMT 2025
|
PRIMARY | |||
|
DBSALT002802
Created by
admin on Tue Apr 01 22:58:11 GMT 2025 , Edited by admin on Tue Apr 01 22:58:11 GMT 2025
|
PRIMARY | |||
|
DTXSID60433294
Created by
admin on Tue Apr 01 22:58:11 GMT 2025 , Edited by admin on Tue Apr 01 22:58:11 GMT 2025
|
PRIMARY | |||
|
9954941
Created by
admin on Tue Apr 01 22:58:11 GMT 2025 , Edited by admin on Tue Apr 01 22:58:11 GMT 2025
|
PRIMARY | |||
|
B66RO93FXQ
Created by
admin on Tue Apr 01 22:58:11 GMT 2025 , Edited by admin on Tue Apr 01 22:58:11 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|